Aptose Biosciences Stock News

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals (EGRX) and Actinium Pharmaceuticals

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eagle Pharmaceuticals

Does Aptose Biosciences (APTO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Encouraging early data on Aptose's lead drug CG-806 has brought more sell-side and institutional investor attention to this small hematology-focused biotech. Th

RBC Capital analyst Gregory Renza maintained a Buy rating on ACADIA Pharmaceuticals (ACAD) on April 6 and set a price target of $58.00. The company's

After SunTrust Robinson and Mizuho Securities gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another Buy, this time

After SunTrust Robinson and Mizuho Securities gave Fate Therapeutics (NASDAQ: FATE) a Buy rating last month, the company received another

RBC Capital analyst Gregory Renza maintained a Buy rating on Aprea Therapeutics (APRE) on March 26 and set a price target of $42.00. The company's shares

In a report released yesterday, Matthew Biegler from Oppenheimer upgraded Homology Medicines (FIXX – Research Report) to Buy, with a

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (ZYNE) and Aptose Biosciences

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals